PGK1 Is a Key Target for Anti-Glycolytic Therapy of Ovarian Cancer: Based on the Comprehensive Analysis of Glycolysis-Related Genes.

导出 LinkOut

翻译打印收藏纠错

第一作者： Rui,Gou

第一单位： Department of Obstetrics and Gynaecology, Shengjing Hospital Affiliated to China Medical University, Shenyang, China.

作者： Rui,Gou ^[1] ; Yuexin,Hu ^[2] ; Ouxuan,Liu ^[1] ; Hui,Dong ^[2] ; Lingling,Gao ^[1] ; Shuang,Wang ^[2] ; Mingjun,Zheng ^[1] ; Xiao,Li ^[2] ; Bei,Lin ^[1]

作者单位： Department of Obstetrics and Gynaecology, Shengjing Hospital Affiliated to China Medical University, Shenyang, China. ^[1] Key Laboratory of Maternal-Fetal Medicine of Liaoning Province, Key Laboratory of Obstetrics and Gynecology of Higher Education of Liaoning Province, Liaoning, China. ^[2] Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany. ^[3]

关键词 NG52 PGK1 Warburg effect anti-glycolytic therapy ovarian cancer

DOI 10.3389/fonc.2021.682461

PMID 34277429

发布时间 2024-04-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2021年11卷

682461页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

PGK1 Is a Key Target for Anti-Glycolytic Therapy of Ovarian Cancer: Based on the Comprehensive Analysis of Glycolysis-Related Genes.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

PGK1 Is a Key Target for Anti-Glycolytic Therapy of Ovarian Cancer: Based on the Comprehensive Analysis of Glycolysis-Related Genes.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除